Medtronic (NYSE:MDT) Price Target Cut to $99.00 by Analysts at BTIG Research

Posted by Francis Steltz on Oct 13th, 2026

Medtronic (NYSE:MDT – Free Report) had its target price decreased by BTIG Research from $100.00 to $99.00 in a report released on Monday morning, MarketBeat reports. BTIG Research currently has a buy rating on the medical technology company’s stock.

Several other brokerages also recently issued reports on MDT. Mizuho set a $115.00 price objective on Medtronic in a research note on Wednesday, September 2nd. Truist Financial reaffirmed a “hold” rating and set a $99.00 target price (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $92.00 target price on shares of Medtronic in a report on Thursday, September 3rd. Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Barclays raised shares of Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Eighteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $102.88.

Get Our Latest Report on Medtronic

Medtronic Price Performance

Shares of NYSE:MDT opened at $91.61 on Monday. The company’s fifty day moving average is $90.38 and its two-hundred day moving average is $84.80. The company has a market cap of $117.18 billion, a P/E ratio of 22.56, a price-to-earnings-growth ratio of 2.02 and a beta of 0.55. Medtronic has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same quarter last year, the firm posted $1.26 earnings per share. Medtronic’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts expect that Medtronic will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is presently 70.94%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medtronic

Several large investors have recently made changes to their positions in the company. HF Advisory Group LLC boosted its holdings in Medtronic by 5.2% during the third quarter. HF Advisory Group LLC now owns 23,577 shares of the medical technology company’s stock valued at $2,034,000 after purchasing an additional 1,165 shares in the last quarter. Valley Wealth Managers Inc. grew its stake in shares of Medtronic by 3.1% in the 3rd quarter. Valley Wealth Managers Inc. now owns 54,193 shares of the medical technology company’s stock valued at $4,676,000 after purchasing an additional 1,631 shares during the period. Atlas Brown Inc. raised its holdings in shares of Medtronic by 5.5% in the 3rd quarter. Atlas Brown Inc. now owns 2,758 shares of the medical technology company’s stock worth $238,000 after buying an additional 145 shares in the last quarter. GK Wealth Management LLC bought a new position in shares of Medtronic during the 3rd quarter worth approximately $162,000. Finally, Decker Wealth Management LLC lifted its position in shares of Medtronic by 2.9% during the 3rd quarter. Decker Wealth Management LLC now owns 44,307 shares of the medical technology company’s stock worth $3,823,000 after buying an additional 1,231 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic said its exchange offer for MiniMed Group shares was oversubscribed. The company plans to exchange all of its remaining 252.8 million MiniMed shares for outstanding Medtronic ordinary shares, completing the disposition of its remaining MiniMed stake. The transaction may simplify Medtronic’s portfolio and reduce exposure to the slower-growth diabetes business. Medtronic Announces Preliminary Results of MiniMed Group Exchange Offer
Positive Sentiment: An investment commentary argued that Medtronic’s underperformance over the past year has left the stock at a modest valuation while its growth outlook is improving. This supports the view that the shares may offer value if operating momentum continues. Medtronic’s Modest Valuation Meets an Improving Growth Outlook
Neutral Sentiment: BTIG Research lowered its price target to $99 from $100 but maintained a Buy rating, implying continued upside based on its valuation assessment. The reduced target is a modest negative, while the retained Buy rating is supportive. Medtronic Price Target Cut by BTIG Research
Neutral Sentiment: Jim Cramer expressed a favorable view of Medtronic but criticized MiniMed, reinforcing the market’s potential preference for Medtronic after the separation. However, the comments are opinion-based and are unlikely to materially affect fundamentals. Jim Cramer’s Views on MiniMed and Medtronic

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.